Actarit

Overview

Actarit (4-Acetylaminophenylacetic acid) is an orally active Carbonic Anhydrase II ( CAII ) inhibitor with an IC 50 of 422 nM. Actarit shows suppressive effects experimental autoimmune encephalomyelitis in rats. Actarit inhibits the development of type ll collagen (CII)-induced arthritis in mice by suppressing delayed-type hypersensitivity to CII. Actarit can be used for the study of Multiple Sclerosis (MS) and rheumatoid arthritis.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Depression | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Carbonic Anhydrase | Products > Signaling Pathways > TNF Receptor | Products > Signaling Pathways > IFNAR

Product Information

• Catalog No.: HY-76938
• CAS No.: 18699-02-0
• Molecular Formula: C10H11NO3
• Molecular Weight: 193.20
• Purity: 99.58%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (12.94 mM); Clear solution
• Availability: In-stock

Source

Original product source